Buy Spiriva Online From Adv-Care Pharmacy
Adv-Care Pharmacy announces the online availability of Spiriva(PRWeb March 10, 2014)Read the full story at http://www.prweb.com/releases/2014/03/prweb11656137.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 11, 2014 Category: Pharmaceuticals Source Type: news
Tiotropium Complements Steroids in Treatment of AsthmaTiotropium Complements Steroids in Treatment of Asthma
The long-acting anticholinergic bronchodilator and selective M3 muscarinic-receptor agonist may help patients whose asthma is not completely controlled with current therapies. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 6, 2014 Category: Consumer Health News Tags: Allergy & Clinical Immunology News Source Type: news
Spiriva Cuts Flares in Heavily Treated Asthma
SAN DIEGO (MedPage Today) -- Tiotropium (Spiriva) Respimat improved lung function and cut exacerbations in severe asthma patients who had already maxed out other treatment options, pooled analysis of two phase III trials showed. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - March 4, 2014 Category: Pediatrics Source Type: news
New Phase III data demonstrate tiotropium Respimat® improves lung function versus placebo and is well tolerated in asthma patients
Boehringer Ingelheim has announced new data from large scale, Phase III studies showing that once-daily tiotropium delivered via the Respimat® Soft Mist™ Inhaler improved lung function and was well tolerated in patients with varying degrees of asthma severity.1 These data were presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2014 annual meeting in San Diego. The first results from the Phase III GraziaTinA-asthma® study demonstrated that tiotropium Respimat® 5 mcg and 2. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 4, 2014 Category: Consumer Health News Tags: Respiratory / Asthma Source Type: news
Boehringer releases positive Phase III trial results of tiotropium Respimat in asthma patients
Boehringer Ingelheim has reported positive results from large-scale Phase III studies demonstrating that once-daily tiotropium delivered via the Respimat inhaler was effective and well-tolerated in patients across asthma severities. (Source: Drug Development Technology)
Source: Drug Development Technology - March 4, 2014 Category: Pharmaceuticals Source Type: news
Minor added benefit of indacaterol/glycopyrronium in COPD
Adults with COPD of moderate or severe severity grade with no more than 2 flare-ups per year have fewer breathing difficulties when treated with the drug combination. According to the findings, the drug combination is better at relieving breathing difficulties (dyspnoea) than a combination treatment with tiotropium and formoterol. However, this only applies to patients who do not yet need inhaled corticosteroids because they have no more than 2 acute flare-ups (exacerbations) per year. Furthermore, there is an indication that the severity of the disease may influence the treatment result, and hence is a so-called "effect m...
Source: ScienceDaily Headlines - February 19, 2014 Category: Science Source Type: news
Pulmonology Top News: Spiriva Signal, LABA Risk
(MedPage Today) -- A heart attack signal with tiotropium (Spiriva) and a potential genetic explanation for severe adverse events with long-acting beta agonists (LABAs) in asthma topped the news in pulmonology this week. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - January 31, 2014 Category: Allergy & Immunology Source Type: news
Heart Attack Signal Found for Spiriva in COPD
(MedPage Today) -- The TIOSPIR trial was used to support safety of the mist inhaler version of tiotropium (Spiriva) compared with dry powder, but the pooled data actually showed something else -- a heart attack signal, researchers argued. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - January 29, 2014 Category: Allergy & Immunology Source Type: news
Week Ahead in Pulmonology: New Allergy Tx? Spiriva Safety
(MedPage Today) -- Is a new ragweed allergy treatment likely to get the FDA green light? Look for that pulmonology news this week, along with more controversy over the link between the tiotropium mist inhaler (Spiriva) and deaths in COPD. (Source: MedPage Today Allergy)
Source: MedPage Today Allergy - January 27, 2014 Category: Allergy & Immunology Source Type: news
COPD and Safety of Tiotropium: Disproving a Negative?COPD and Safety of Tiotropium: Disproving a Negative?
The authors of a new study seek to determine the safety and efficacy of different formulations of tiotropium as a COPD therapy. Medscape Pulmonary Medicine (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - January 6, 2014 Category: Internal Medicine Tags: Pulmonary Medicine Commentary Source Type: news
Featured in NEJM Journal Watch: Tiotropium Benefits Some Patients Who Don't Respond to Beta-Agonists (FREE)
By the NEJM Journal Watch Editors
In a study … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 3, 2013 Category: Primary Care Source Type: news
Boehringer seeks European approval for expanded indication of tiotropium Respimat
German pharmaceutical firm Boehringer Ingelheim has submitted European marketing authorisation (MA) applications to extend the indication to use tiotropium (Spiriva) Respimat for the treatment of asthma in adults aged 18 years and over. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - November 15, 2013 Category: Pharmaceuticals Source Type: news
Tiotropium Safety: Powder vs Soft Mist Formula for COPDTiotropium Safety: Powder vs Soft Mist Formula for COPD
How does the soft mist formulation of tiotropium stack up against the powder formula in terms of safety and efficacy for COPD? Medscape Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 7, 2013 Category: Consumer Health News Tags: Pulmonary Medicine Viewpoint Source Type: news
Indacaterol and Tiotropium Similar in Effect and SafetyIndacaterol and Tiotropium Similar in Effect and Safety
Indacaterol and tiotropium are 'equally effective' in patients with severe chronic obstructive pulmonary disease and a history of serious exacerbations, new data show. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 30, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
Tiotropium Respimat as Safe as HandiHalerTiotropium Respimat as Safe as HandiHaler
A study of 17,000 COPD patients settles it: mortality rates with tiotropium Respimat and tiotropium HandiHaler are equivalent. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 18, 2013 Category: Consumer Health News Tags: Pulmonary Medicine News Source Type: news
